Benign prostatic hyperplasia
ICD-10 N40 ICD-11 GA90

Refractory Prostatic Hematuria in BPH After 5-Alpha Reductase Inhibitor Therapy Has Failed

In benign prostatic hyperplasia, refractory hematuria originating from prostatic bleeding represents a distinct clinical challenge — particularly when a structured first-line pharmacological approach has not achieved the desired outcome.

Clinical Scenario

This protocol applies to men with BPH presenting with refractory hematuria due to prostatic bleeding, after other causes of hematuria have been excluded. In this population, 5-alpha reductase inhibitor (5-ARI) therapy is an appropriate first-line approach targeting reduction or cessation of hematuria.

When First-Line Treatment Has Not Worked

When first-line therapy with a 5-alpha reductase inhibitor — either finasteride or dutasteride — fails to achieve reduction or cessation of hematuria, the clinical situation requires escalation to the next step.

Next-Step Approach

When gross hematuria persists despite 5-ARI therapy, a surgical intervention targeting the adenomatous tissue is the approach outlined in this protocol. The specific procedure, conditions, and full decision pathway are detailed in the complete protocol…

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000003698

After exclusion of other causes of hematuria, 5-ARIs may be an appropriate and effective treatment alternative in men with refractory hematuria presumably due to prostatic bleeding.

If, however, gross hematuria persists, surgical removal/ablation of the offending adenomatous tissue should be the next step unless precluded for other reasons.

View source ↗